This has resulted in the mass spec utility in biomarker standardization efforts. According to Seegmiller, most large clinical laboratories are now incorporating mass spectrometry systems in their testing repertoire.” Mass spectrometry can help “bridge a gap that has existed for clinical trials and various research studies by obtaining results from a mass spectrometry platform to perform analyses not possible using standard clinical analyzer systems.” One of the most impressive benefits of these systems is the analytical specificity advantages they provide. “Mass spectrometry is increasingly being integrated into clinical laboratories,” said center director Jesse Seegmiller. The recent expansion of its Mass Spectrometer Center will enable ARDL to bring “gold standard” analysis more fully into its clinical testing operations and help investigators study renal, diabetes, nutritional, cardiovascular and other diagnostic biomarkers. Marc Jenkins and his lab in developing an antibody test that has proven to be so reliable.”įor more than three decades, scientists in the Advanced Research and Diagnostic Laboratory (ARDL) at the University of Minnesota have conducted large-scale analysis of biological specimens for NIH-sponsored multi-center clinical trials. “We were positioned for this opportunity thanks to the efforts of Dr. “We are looking forward to joining this important effort to help expand our knowledge surrounding immunity to COVID-19,” said Amy Karger, MD, PhD, an associate professor in the department and the principal investigator for the initiative, who leads the University’s Advanced Research and Diagnostic Laboratory, where a majority of the state’s serology work takes place. SeroNet is a major component of the National Cancer Institute’s (NCI) response to the pandemic and is included in an emergency Congressional appropriation of $306 million to the Institute “to develop, validate, improve and implement serological testing and associated technologies.” As part of the Serological Sciences Network (SeroNet), the team received a five-year, $6.7 million grant to support their part of the network's research effort. 8, 2020 - The University of Minnesota Medical School’s Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |